Transgenomic (NASDAQ: PRPO) and Voyager Therapeutics (NASDAQ:VYGR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Risk and Volatility

Transgenomic has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 4.54, meaning that its stock price is 354% more volatile than the S&P 500.

Earnings & Valuation

This table compares Transgenomic and Voyager Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Transgenomic $1.55 million 7.30 -$7.61 million N/A N/A
Voyager Therapeutics $14.22 million 32.01 -$40.19 million ($2.84) -5.95

Transgenomic has higher revenue, but lower earnings than Voyager Therapeutics.

Profitability

This table compares Transgenomic and Voyager Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Transgenomic -536.28% N/A -108.93%
Voyager Therapeutics -1,195.63% -60.63% -42.18%

Insider & Institutional Ownership

6.7% of Transgenomic shares are held by institutional investors. Comparatively, 40.7% of Voyager Therapeutics shares are held by institutional investors. 1.9% of Transgenomic shares are held by company insiders. Comparatively, 8.0% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Transgenomic and Voyager Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Transgenomic 0 0 0 0 N/A
Voyager Therapeutics 0 1 10 0 2.91

Given Voyager Therapeutics’ higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Transgenomic.

Summary

Voyager Therapeutics beats Transgenomic on 8 of the 11 factors compared between the two stocks.

About Transgenomic

Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.

About Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain. The Company’s clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson’s disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Receive News & Ratings for Transgenomic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgenomic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.